Human bone marrow mesenchimal stem cells growth rate dynamics, immunophenotype and genetic stability on early and late passages at  ex vivo  culturing

E. Yu. Osipova; Осипова Е. Ю.; V. A. Nikitina; Никитина В. А.; T. A. Astrelina; Астрелина Т. А.; A. Yu. Ustyugov; Устюгов А. Ю.; E. V. Dmitrieva; Дмитриева Е. В.; B. B. Purbueva; Пурбуева Б. Б.; E. V. Skorobogatova; Скоробогатова Е. В.; T. V. Schamanckaya; Шаманская Т. В.; Z. M. Dischlevaya; Дышлевая З. М.; M. V. Yakovleva; Яковлева М. В.; O. A. Maiorova; Майорова О. А.; L. D. Katosova; Катосова Л. Д.; S. A. Roumiantsev; Румянцев С. А.; N. P. Bochkov; Бочков Н. П.

doi:10.17650/1818-8346-2009-0-1-44-50

Human bone marrow mesenchimal stem cells growth rate dynamics, immunophenotype and genetic stability on early and late passages at ex vivo culturing

Authors: Osipova E.Y.¹^,2, Nikitina V.A.³, Astrelina T.A.¹^,2, Ustyugov A.Y.², Dmitrieva E.V.¹, Purbueva B.B.¹^,2, Skorobogatova E.V.¹, Schamanckaya T.V.¹^,2, Dischlevaya Z.M.¹, Yakovleva M.V.², Maiorova O.A.¹^,2, Katosova L.D.³, Roumiantsev S.A.¹^,2, Bochkov N.P.³
Affiliations:
1. Federal Research Center of Pediatric Hematology, Oncology and Immunology
2. The Stem cell bank Moscow Department of Public health
3. Medical Genetic Scientific Centre RAMS
Issue: No 1 (2009)
Pages: 44-50
Section: ФУНДАМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ
Published: 24.02.2009
URL: https://oncohematology.abvpress.ru/ongm/article/view/710
DOI: https://doi.org/10.17650/1818-8346-2009-0-1-44-50
ID: 710

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Human mesenchimal stem cells (MSC) growth dynamics, immunophenotype change, genetic stability on early (3—4) and late (10—12) passages at in vitro culturing was studied. Results of bone marrow stromal fibroblasts culturing (n=25) from allogeneic transplant recipients with hematological disorders are presented. It has been shown, that in MSC population cultivated in vitro linear homogeneity of cells is observed on 3—4 passage, and remains on 10—12 passage. Clonal heterogeneities of MSC population and selective advantage of certain clones during culturing was revealed as aneuploidy analysis results of cultivated cells. The MSC culturing protocol used in our work allows receiving well characterized MSC number sufficient for clinical application as early as 3—4 passage. While using in the therapeutic purposes MSC later terms of expansion it is necessary to have close control of cells immunophenotype and genetic stability, which will allow avoiding in the future the undesirable long-term consequences of MSC cultures clinical use. The obtained data are discussed and compared with literature data.